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Pluripotent stem cells (PSCs) have been classified into two distinct states: a primitive, naive LIF-dependent
state represented by murine ESCs, and a primed bFGF-dependent state observed in murine and rat epiblast
stem cells (EpiSCs). The vast similarities between EpiSCs and human ESCs suggest that, despite their blas-
tocyst origin, human ESCs exist in a primed pluripotent state. Recent findings demonstrate that the naive and
primed pluripotent states are interconvertible, even in human cells, and hint that growth factor-mediated
Nanog expression may be an important factor regulating the balance between them.Pluripotent Stem Cells
Embryonic stem cells (ESCs) are pluripotent stem cells derived
from the inner cell mass (ICM) of the preimplantation blastocyst,
which have the ability to generate all three germ layers,
ectoderm, mesoderm, and endoderm (Yu and Thomson, 2008).
ESCs have been derived from both murine and human blasto-
cysts, but curiously, ESC lines from these two species display
profound differences in colony morphology, proliferation rate,
growth factor requirements, and epigenetic status (Table 1).
Murine ESCs grow in three-dimensional, tightly packed colonies
with a population doubling time of approximately 16 hr and
require LIF and BMP4 growth factor signaling for their continued
self-renewal. In contrast, human ESCs form flattened two-
dimensional colonies and are maintained in a bFGF and
ActivinA/TGF-b signaling-dependent manner. Human ESCs
proliferate slowly, with a population doubling time averaging 36
hr. Epigenetically, human and murine ESCs display a different
pattern of X chromosome inactivation and promoter occupancy
by pluripotency transcription factors (Hanna et al., 2009). In
addition, cultures of human ESCs are split by mechanical- or
collagenase-mediated passaging as small clusters of cells, and
unlike murine ESCs, most human ESC lines cannot be passaged
as single cells by trypsin digest (Yu and Thomson, 2008). Similar
differences are observed between murine and human induced
pluripotent stem cells (iPSCs), which are derived through the
ectopic expression of pluripotency transcription factors (Oct4,
Sox2, Klf4, and c-Myc) in somatic cells (Takahashi and Yama-
naka, 2006; Okita et al., 2007; Takahashi et al., 2007).
Distinct Pluripotent States
Until recently the differences between mESCs and hESCs were
thought to be variations of an otherwise comparable pluripotent
population. This view was challenged by the derivation of
so-called epiblast stem cells (EpiSCs) from explanted murine
or rat postimplantation epiblasts. EpiSCs demonstrate striking
similarities to hESCs with regard to their molecular properties,
growth factor requirements, colony morphology, X-inactivation
status, and culture dynamics (Tesar et al., 2007; Brons et al.,2007; Guo et al., 2009). These results demonstrate that in the
mouse, two functionally distinct pluripotent states exist:
a ‘‘naive’’ LIF-dependent pluripotent stem cell (PSC) state that
is compatible with the preimplantation ICM and a ‘‘primed’’
bFGF-dependent PSC state that is reminiscent of the postim-
plantation epiblast (Nichols and Smith, 2009). The naive pluripo-
tent state represents a more primitive stem cell population than
the primed PSCs, in that they are uniquely capable of integrating
with the blastocyst ICM and contribute to chimera formation.
In addition, naive PSCs exhibit a more open chromatin structure,
as demonstrated by the lack of X-inactivation (Hanna et al.,
2010). In accordance with this notion, EpiSCs fail to integrate
into the preimplantation blastocyst and rarely contribute to
chimera formation (Tesar et al., 2007). The strong observed
overlap of the key characteristics of EpiSCs and human ESCs
suggest that despite their blastocyst origin, human ESCs exist
in a primed pluripotent state. It has been argued that the blasto-
cyst origin of human ESCs is evidenced by their expression of
Rex1 (Zfp42), known to be a specific marker of the ICM in murine
embryos. However, the ICM specificity of this marker has not
been established for the human embryo. Molecular examination
of blastocysts across different species, including humans,
demonstrates that a wide variation exists in the developmental
timing of the expression of early regulators of embryonic devel-
opment such as Oct4 and Cdx2 (Kuijk et al., 2008; Pant and
Keefer, 2009; Chen et al., 2009). It is possible that in human
development, Rex1 expression is similarly extended into the
early postimplantation epiblast, explaining its expression in
human ESCs and iPSCs.
The naive murine PSC state is maintained by an intricate
balance between LIF and BMP4 growth factor signals. LIF acti-
vates three distinct intracellular signaling pathways: the Jak/
Stat3 and PI(3)K/Akt pathways that stimulate self renewal and
the MEK/ERK pathway that drives mESC differentiation
(Figure 1; Niwa et al., 2009; Hamazaki et al., 2006). BMP4 serves
to inhibit this differentiation-inducing effect of the MEK/ERK
pathway through upregulation of Inhibitor of Differentiation (Id)
proteins (Ying et al., 2003). Thus, it appears that in naive murineCell Stem Cell 7, November 5, 2010 ª2010 Elsevier Inc. 559
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N/D SSEA1 positive Hanna et al., 2009
Rat 2ib+LIF or 3ia teratoma, germline
transmission
active SSEA1 positive Buehr et al., 2008
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N/D SSEA1 negative Buecker et al., 2010
Human 2ib+LIF, 4 factorsf teratoma N/D SSEA4/Tra1-60/
Tra1-81




FGF/ActivinA teratoma inactive SSEA1 negative Tesar et al., 2007
Mouse
(nonpermissive)
FGF/ActivinA teratoma N/D SSEA1 negative Brons et al., 2007
Rat FGF/ActivinA teratoma N/D SSEA1 negative Brons et al., 2007
Human FGF/ActivinA teratoma inactive SSEA4/Tra1-60/
Tra1-81
positive Thomson et al., 1998
N/D: not done.
a FGFR, GSK3b, and MEK/ERK inhibition.
bGSK3b and MEK/ERK inhibition.
c Constitutive expression of Oct4, Sox2, Klf4, and cMyc.
d Transient expression of Oct4+Klf4 or Klf2+Klf4.
e Constitutive expression of Oct4, Sox2, Klf4, cMyc, and Nanog.
f Lentiviral expression of Oct4, Sox2, Nanog, and Lin28.
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tiation signals downstream of the LIF and BMP4 receptors. In
line with this idea, Ying and colleagues demonstrated that
mESCs can be maintained in the absence of ectopic signals
when intracellular differentiation inducing signals are eliminated.
Simultaneous inhibition of the FGF receptor tyrosine kinase,
MEK/ERK signaling, and GSK3b, the so-called 3i culture regime,
are able to sustain LIF-independent growth and self-renewal of
mESCs (Ying et al., 2008), demonstrating that in the absence
of differentiation cues, mESC self-renewal prevails over differen-
tiation.
The primed pluripotent stem cell state is maintained by
a combination of ActivinA/TGF-b and bFGF signaling. The Acti-
vinA/TGF-b pathway leads to activation of SMAD2/3, which is
a direct upstream inducer of NANOG expression (Figure 1; Xu
et al., 2008; Vallier et al., 2009). The function of the bFGFsignaling
pathway is less clear and may be divergent between hESCs and
murine EpiSCs. In human ESCs, bFGF inhibits neural develop-
ment and cooperateswith SMAD2/3 tomaintain NANOGexpres-
sion, whereas in murine EpiSCs, bFGFwas not observed to have
a stimulatory effect on Nanog expression (Greber et al., 2010).560 Cell Stem Cell 7, November 5, 2010 ª2010 Elsevier Inc.Importantly, and in support of themodel that naive and primed
states represent different ‘‘flavors’’ of pluripotency, naive and
primed cells are readily interconvertible. For example, naive
mESCs adopt a primed EpiSC state upon a simple growth factor
switch to bFGF/ActivinA (Guo et al., 2009). The conversion of
primed PSCs to the naive pluripotent state is less efficient but
can be facilitated by the overexpression of Klf4, Klf2, Nanog,
or Nr5a (Guo et al., 2009; Guo and Smith, 2010; Silva et al.,
2009). In addition, Bao and colleagues demonstrated that
EpiSCs can also revert to ESC-like cells (rESCs) upon prolonged
passaging of the stem cells in the presence of LIF and selection
for cells that express the germ cell-specific marker Stella
(Dppa3) (Bao et al., 2009). However, this growth factor-mediated
conversion of EpiSCs to rESCs may be indirect. With the same
Stella-GFP reporter cell line, Hayashi and colleagues recently
demonstrated that EpiSCs can form primordial germ cells
(PGCs) in vitro (Hayashi and Surani, 2009). PGCs can give rise
to embryonic germ cells (EGCs) that are nearly indistinguishable
from ESCs, so it is possible that the rESCs reported by Bao and
colleagues are in fact EGCs derived from intermediate PGCs
(Bao et al., 2009; Guo and Smith, 2010). Whether indirect or
Figure 1. Exogenous Growth Factor Signals Regulate Nanog
Expression Levels
In naive pluripotent stem cells, LIF stimulation results in activation of the PI(3)K/
Akt, Stat3, and MEK/ERK signaling pathways. Stat3 and PI(3)K/Akt positively
regulate self-renewal (as indicated by solid arrows): PI(3)K/Akt acts via T-Box3
and Stat3 acts via stimulating Klf4 expression. In contrast, activation of MEK/
ERK signaling inhibits Nanog expression (dashed arrow), but this pathway is
inhibited by BMP4 signals through upregulation of Id proteins. Activation of
PKA signaling by G protein-coupled receptors can stabilize the naive pluripo-
tent state by maintaining Nanog expression levels through an unknown
signaling mechanism. In primed pluripotent stem cells, ActivinA/TGF-b growth
factor signaling induces Nanog expression via the SMAD2/3 binding site found
in the Nanog promotor. Additional cooperative activation via bFGF was shown
in human ESCs, but may not play a role in Nanog expression in murine EpiSCs.
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to rESC conversion. Whereas the 3i regime can support the
maintenance of naive murine PSCs, the conversion of murine
EpiSCs into rESCs is impaired in the absence of LIF signaling
(Yang et al., 2010). Ectopic expression of constitutively active
Stat3 restored the EpiSC to rESC conversion, demonstrating
that this pathway plays a critical role in establishing the naive
pluripotent state (Yang et al., 2010).Metastable Pluripotent Stem Cells
Curiously, the naive PSC state is only maintained in lines derived
from a limited set of ‘‘permissive’’ inbred mouse strains. Until
recently, naive PSC lines could not be derived from nonpermis-
sive mouse strains such as the widely used nonobese diabetic
(NOD) mice. This limitation severely hampered the development
of novel genetic models in these backgrounds. Hanna and
colleagues demonstrated that in nonpermissive genetic back-
grounds, the naive PSC state depends on the continued
presence of exogenous factors, either the constitutive expres-
sion of ectopic reprogramming factors (Klf4 or cMyc) or the
presence of small molecule inhibitors of the GSK3b and MEK/
ERK signaling pathways (Hanna et al., 2009), so-called 2i+LIF
conditions. Upon withdrawal of these exogenous factors, the
nonpermissive naive PSCs rapidly differentiate. Similar strate-
gies allowed the derivation of naive PSCs from the rat either byectopic expression of all four reprogramming factors, Oct4,
Sox2, Klf4, and cMyc (Liao et al., 2009), or by using a chemical
inhibitor cocktail in the form of 3i or 2i+LIF (Buehr et al., 2008).
Importantly, naive rat PSCs were shown to be amenable to
homologous recombination and allowed the generation of
knockout rats (Tong et al., 2010), demonstrating that the naive
PSC state offers functional advantages over primed PSCs.
The results discussed above demonstrate that the naive
pluripotent state is not restricted to murine PSCs but requires
the stabilization by exogenous factors in order to be maintained
in other species. Three recent reports suggest that alternative
states exist for human PSCs as well. Li and colleagues demon-
strated that human iPSCs could be derived in the presence of
2i+LIF (Li et al., 2009). In these conditions, the human iPSCs
adopt murine ESC-like colony morphology and are propagated
as single cells by trypsin digest. However, the molecular and
functional properties of the cells were not reported and their
cell-surfacemarker profile suggests that the cells retain a degree
of similarity to ‘‘traditional’’ primed human iPSCs. More recently,
our lab demonstrated that reprogramming of somatic cells via
Oct4, Sox2, Klf4, c-Myc, and Nanog under naive growth factor
conditions results in cells termed hLR5 (human, LIF, and
5 reprogramming factors) that resemble murine ESCs with
regard to their colonymorphology, culture dynamics, and certain
molecular properties (Buecker et al., 2010). Maintenance of the
hLR5 state depends on the continued expression of ectopic
reprogramming factors. Furthermore, hLR5 cells did not form
differentiated derivatives and are therefore strictly speaking not
pluripotent. However, hLR5 cells convert to a stable primed
pluripotent state when switched to ‘‘standard’’ bFGF culture
conditions. Importantly, hLR5 cells allow efficient homologous
recombination-mediated gene targeting via standard protocols
that are routinely used for murine ESCs and can thus serve as
a powerful intermediate for the genetic manipulation of human
PSCs. With a similar approach, Hanna and colleagues derived
naive human PSCs by combining ectopic expression of Oct4
and Klf4 or Klf4 and Klf2 with small molecule inhibitors of
GSK3b and MEK/ERK (Hanna et al., 2010). Importantly, the
authors demonstrated that forskolin, an agonist of the Protein
Kinase A pathway, can transiently replace the need for ectopic
reprogramming factors. Interestingly, forskolin is also used for
the derivation of embryonic germ cell lines from embryonic
gonads, suggesting a close relationship between naive pluripo-
tency and the germline. Indeed, the expression of germ cell-spe-
cific genes appears to be a hallmark property of naive PSCs
(Chou et al., 2008; Tesar et al., 2007; Hanna et al., 2010). In the
absence of ectopic reprogramming factors, the maintenance of
human naive LIF-dependent PSCs is limited to approximately
15 passages. Taken together, these combined results suggest
that a naive LIF-dependent pluripotent state can exist in multiple
species, including humans. The specific growth factor condi-
tions that maintain this state in the absence of ectopic reprog-
ramming factors or small molecule inhibitors remain poorly
understood.
Nanog as a Mediator of the Pluripotent State
The transcription factors Oct4, Sox2, and Nanog are at the heart
of the stem cell transcriptional pluripotency network and
together maintain pluripotency (reviewed in Barrero et al., 2010Cell Stem Cell 7, November 5, 2010 ª2010 Elsevier Inc. 561
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and Tomlinson, 2009). So how can two distinct sets of growth
factors (LIF and Bmp4 versus bFGF and ActivinA) signal to define
and maintain two discrete pluripotent states via the same tran-
scriptional regulators of pluripotency, Oct4, Sox2, and Nanog?
Of the three core factors, only Nanog has been shown to be
a downstream target of both sets of growth factor pathways
and thus Nanog is an attractive candidate as a key regulator of
the pluripotent stem cell state.
Nanog was first described by two independent groups in
a screen for genes that can bestow LIF-independent growth on
mESCs (Chambers et al., 2003; Mitsui et al., 2003). Nanog
knockout studies demonstrated that although Nanog is not
required for maintaining pluripotency, Nanog/ ESCs are more
prone to differentiation (Chambers et al., 2007). In addition, in
the absence of Nanog, the derivation of naive PSCs is impaired,
demonstrating that Nanog plays an important role in establishing
a pluripotent state (Silva et al., 2009). Several signaling pathways
emanating from the LIF and ActivinA/TGF-b receptors were
recently shown to regulateNanog expression. Niwa et al. demon-
strated that in mESCs, LIF-induced activation of PI(3)K/AKT
induces T-Box3 (Tbx3) expression,which in turnactivatesNanog
transcription (Figure 1; Niwa et al., 2009). In addition, parallel acti-
vation of the Jak/Stat3 pathway induces Klf4 expression, which
binds to the Nanog promotor and further simulates Nanog
expression (Niwa et al., 2009; Zhang et al., 2010). Xu and
colleagues discovered SMAD2/3 binding sites in the human
Nanog promotor, suggesting a direct effect of ActivinA/TGF-b
signaling on Nanog expression in human ESCs. Indeed, ActivinA
stimulation of human ESCs leads to enhanced activity of the
Nanog promoter, whereas mutations of the SMAD2/3 binding
sites abrogate this responsiveness (Figure 1; Xu et al., 2008).
Interestingly, Nanog expression levels are heterogeneous
within a mESC colony and heterogeneity is reestablished when
Nanog-GFP mESCs are sorted into Nanoghigh and Nanoglow
subpopulations (Chambers et al., 2007; Kalmar et al., 2009).
The percentage of Nanoghigh cells is greatly increased under 3i
culture conditions, demonstrating that high Nanog expression
levels are closely linked to the inhibitor-enforced naive ESC state
(Wray et al., 2010). In contrast, Nanoglow cells within the ESC
culture are more prone to differentiation, suggesting that low
Nanog levels lead to a more primed pluripotent state (Chambers
et al., 2007). Indeed, overexpression of Nanog facilitates the
LIF-mediated conversion of EpiSCs into mESCs (Silva et al.,
2009). These combined data suggest that the different sets of
exogenous growth factors that support naive and primed PSCs
promote a particular pluripotent state by maintaining different
levels of Nanog expression. The recent generation of Nanog-
GFP knockin human ESCs demonstrates that Nanog exhibits
heterogeneous expression in human ESCs as well, but it remains
to be analyzed whether similar functional differences exist
between NANOGlow and NANOGhigh human ESCs (Fischer
et al., 2010).
Nanog and Naive Pluripotent Stem Cells
The above data suggest that in nonpermissive species, the naive
pluripotent state is stabilized by the induction of Nanog expres-
sion, either by ectopic reprogramming factors or by small mole-
cule inhibitors of differentiation. Indeed, Klf4 and/or Klf2 are562 Cell Stem Cell 7, November 5, 2010 ª2010 Elsevier Inc.upstream regulators of Nanog and are required to induce the
transition of primed human PSCs to a naive pluripotent state
(Hanna et al., 2010). In human PSCs, the combined inhibition
of GSK3b and MEK/ERK is still insufficient to maintain the naive
PSC state in the absence of ectopic reprogramming factors.
However, the addition of forskolin, a PKA activator, allows the
maintenance of naive iPSCs for up to 15 passages. PKA is
commonly activated as a result of G protein coupled receptor
(GPCR) activation and concomitant elevation of intracellular
cAMP levels. The role of GPCR signaling in PSC maintenance
is not well understood, but two reports suggest that elevation
of intracellular cAMP levels stabilizes Oct4 and Nanog expres-
sion and can delay mESC differentiation upon LIF withdrawal
(Faherty et al., 2007; Layden et al., 2010).
Considering how growth factor signals, reprogramming factor
activity, and/or small molecule inhibitors seem to converge on
Nanog, it seems reasonable to propose that additional growth
factor signals that enhance Nanog expression levels may
stabilize the naive human PSC state. Further exploration of the
PKA signaling pathway, the identification of the relevant GPCR
receptor and ligand, and the link between PKA signaling and
Nanog expression may identify additional growth factor signals
that sustain the stable, long-term propagation of naive human
iPSCs and perhaps allow the derivation of naive human ESCs
from blastocyst embryos.
New Applications of Naive Human PSCs
The naive human pluripotent state offers several advantages
over existing human ESC and iPSC lines. Homologous recombi-
nation-mediated gene targeting is much enhanced in naive
pluripotent stem cells, perhaps because of the more open
chromatin structure of these cells (Hanna et al., 2009; Buecker
et al., 2010; Tong et al., 2010). As such, naive PSCs can enable
the generation of mutant or transgenic human cell lines to model
disease and development. In addition, the targeted correction of
mutations in patient-derived naive iPSCs would be an elegant
way to restore normal organ function in future cell therapies.
Moreover, maintaining human PSCs in the naive pluripotent
state may help eliminate the large variation in developmental
propensity observed among primed human PSC lines and
even within a single, heterogeneous cell line (Osafune et al.,
2008; Newman and Cooper, 2010; Guenther et al., 2010;
Chin et al., 2010), increasing consistency in the results generated
by different labs. Finally, naive pluripotent stem cells are uniquely
able to integrate into the blastocyst ICM and functionally
contribute to the developing embryo. Although no responsible
group would propose to apply blastocyst complementation to
developing human embryos, there are both basic and applied
experimental settings that could eventually benefit from the
unique functional properties of naive human PSCs. For example,
in a series of elegant experiments, Kobayashi and colleagues
recently demonstrated that naive rat pluripotent stem cells can
integrate across species boundaries into mouse blastocyst
embryos and form viable chimeras (Kobayashi et al., 2010).
Although the overall percentage of rat cells contributing to the
hybrid embryo was low, the rat donor cells were able to form
an entire pancreas in recipient mouse embryos in which the
pancreas was genetically ablated. Human ESCs have been
injected into murine blastocysts in the past but did not
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2006). The above experiments with naive rat PSCs suggest
that in the naive state, human PSCs may be developmentally
compatible with blastocysts of other species. Such experiments
will undoubtedly raise justifiable concerns and debate over the
moral implications of cross-species chimeras (discussed in
Solter, 2010). Nonetheless, in the right genetic background
and perhaps in a larger animal host such as the pig, cross-
species chimeras may serve as a feasible approach for the
generation of autologous human tissues for organ transplanta-
tion.
In basic research, naive human PSCs will provide a critical tool
to model the earliest steps in human embryonic development, as
they are expected to be more closely related to the blastocyst
ICM than current human ESC lines. Their unique primitive state
will allow the study of critical epigenetic processes during early
differentiation, such as, for example, X-inactivation. However,
although initial attempts at deriving naive human iPSCs are
promising, the culture (growth factor) conditions that support
the long-term maintenance of these cells remain elusive.
Ultimately, naive human ESCs will need to be generated from
blastocyst embryos as well. Such experiments will raise ethical
challenges of their own that should be subject to strict oversight.
Nonetheless, it is clear that comparison studies regarding the
functional behavior of embryo- and reprogramming-derived
pluripotent cells from different species has been, and will
continue to be, a valuable area of experimental inquiry.
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